|1.||Harris, Heather A: 4 articles (12/2006 - 10/2003)|
|2.||Keith, James C: 2 articles (02/2006 - 10/2003)|
|3.||Yao, Pei-Li: 1 article (02/2014)|
|4.||Kopelovich, Levy: 1 article (02/2014)|
|5.||Gonzalez, Frank J: 1 article (02/2014)|
|6.||Peters, Jeffrey M: 1 article (02/2014)|
|7.||Srivastava, Ritesh K: 1 article (02/2014)|
|8.||Weng, Zhiping: 1 article (02/2014)|
|9.||Afaq, Farrukh: 1 article (02/2014)|
|10.||Arumugam, Aadithya: 1 article (02/2014)|
|1.||Skin Neoplasms (Skin Cancer)
02/01/2014 - "In this issue of the journal, Chaudhary and colleagues demonstrate markedly decreased ultraviolet B (UVB)-induced skin cancer in a mouse model using a highly specific ER-β agonist, ERB-041. "
02/01/2014 - "Our results show that Erb-041 is a potent skin cancer chemopreventive agent that acts by dampening the WNT/β-catenin signaling pathway."
02/01/2014 - "The WNT/β-catenin signaling pathway, which underlies pathogenesis of skin cancer, was found to be downregulated by Erb-041 treatment. "
02/01/2014 - "Collectively, the results from these studies provide important new insights into the mechanisms by which the ER-β agonist ERB-041 inhibits UVB-induced skin cancer and opens the door for future studies that could examine combinatorial approaches for UVB-dependent skin cancer chemoprevention."
11/01/2010 - "This study aimed to compare the efficacy and safety of one of these agonists, ERB-041, in subjects with rheumatoid arthritis (RA). "
11/01/2010 - "Efficacy and safety of a selective estrogen receptor β agonist, ERB-041, in patients with rheumatoid arthritis: a 12-week, randomized, placebo-controlled, phase II study."
12/28/2006 - "ERB-041 (2-(3-Fluoro-4-hydroxyphenyl)-7-vinyl-1,3 benzoxazol-5-ol) is a selective estrogen receptor-beta agonist with activity in rodent models of rheumatoid arthritis and endometriosis. "
11/01/2010 - "Although well tolerated and safe, ERB-041 failed to demonstrate antiinflammatory efficacy in RA patients, despite evidence of strong activity in preclinical arthritis models. "
02/01/2006 - "A small-molecule ERbeta selective agonist, ERB-041, has potent antiinflammatory activity in the Lewis rat model of adjuvant-induced arthritis. "
10/01/2003 - "However, ERB-041 has a dramatic beneficial effect in the HLA-B27 transgenic rat model of inflammatory bowel disease and the Lewis rat adjuvant-induced arthritis model. "
04/01/2005 - "ERB-041 is a selective estrogen receptor-beta (ERbeta) agonist that has anti-inflammatory activity in preclinical models of arthritis and inflammatory bowel disease, but is inactive in many preclinical models of classic estrogen activity. "
02/01/2006 - "Organ messenger ribonucleic acid and plasma proteome changes in the adjuvant-induced arthritis model: responses to disease induction and therapy with the estrogen receptor-beta selective agonist ERB-041."
|2.||Estrogen Receptor beta
|4.||NF-kappa B (NF-kB)
|5.||HLA-B27 Antigen (HLA B27 Antigen)
|6.||Mifepristone (RU 486)
|7.||RNA (Ribonucleic Acid)